GEAP202516774A - Compactable oral formulations of ibutamoren - Google Patents

Compactable oral formulations of ibutamoren

Info

Publication number
GEAP202516774A
GEAP202516774A GEAP202516774A GEAP2025016774A GEAP202516774A GE AP202516774 A GEAP202516774 A GE AP202516774A GE AP202516774 A GEAP202516774 A GE AP202516774A GE AP2025016774 A GEAP2025016774 A GE AP2025016774A GE AP202516774 A GEAP202516774 A GE AP202516774A
Authority
GE
Georgia
Prior art keywords
ibutamoren
compactable
oral formulations
hardening
abstract
Prior art date
Application number
GEAP202516774A
Other languages
English (en)
Georgian (ka)
Inventor
John C Mckew
Alpa B Parikh
Original Assignee
Lumos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumos Pharma Inc filed Critical Lumos Pharma Inc
Publication of GEAP202516774A publication Critical patent/GEAP202516774A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GEAP202516774A 2022-11-03 2022-11-22 Compactable oral formulations of ibutamoren GEAP202516774A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263422329P 2022-11-03 2022-11-03

Publications (1)

Publication Number Publication Date
GEAP202516774A true GEAP202516774A (en) 2025-06-25

Family

ID=90835855

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP202516774A GEAP202516774A (en) 2022-11-03 2022-11-22 Compactable oral formulations of ibutamoren

Country Status (12)

Country Link
US (2) US11969416B1 (enExample)
EP (1) EP4611737A1 (enExample)
JP (2) JP7872443B2 (enExample)
KR (1) KR20250107210A (enExample)
CN (1) CN120239602A (enExample)
AU (1) AU2022485048A1 (enExample)
CL (1) CL2025001309A1 (enExample)
CO (1) CO2025007025A2 (enExample)
GE (1) GEAP202516774A (enExample)
IL (1) IL320529A (enExample)
MX (1) MX2025005154A (enExample)
WO (1) WO2024096892A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
JPH11513989A (ja) 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬の湿式造粒製剤
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
ES2710665T3 (es) * 2006-03-15 2019-04-26 Michael O Thorner Métodos para el tratamiento de la sarcopenia con un secretagogo de hormona de crecimiento
FI20080351A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
WO2014030204A1 (ja) * 2012-08-20 2014-02-27 大日本住友製薬株式会社 薬物含有中空粒子
CA2889499C (en) * 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
MX378261B (es) * 2013-03-14 2025-03-10 Redhill Biopharma Ltd Formas de dosificación sólidas de liberación prolongada antieméticas.
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症
EP4467158A3 (en) * 2018-02-14 2025-02-19 Lumos Pharma, Inc. Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Also Published As

Publication number Publication date
US12390452B2 (en) 2025-08-19
US20240156793A1 (en) 2024-05-16
US11969416B1 (en) 2024-04-30
JP2025535941A (ja) 2025-10-30
IL320529A (en) 2025-06-01
JP7872443B2 (ja) 2026-06-09
KR20250107210A (ko) 2025-07-11
EP4611737A1 (en) 2025-09-10
JP2026027432A (ja) 2026-02-18
CN120239602A (zh) 2025-07-01
AU2022485048A1 (en) 2025-05-22
WO2024096892A1 (en) 2024-05-10
CO2025007025A2 (es) 2025-07-17
CL2025001309A1 (es) 2025-09-26
MX2025005154A (es) 2025-07-01
US20240245663A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
GEAP202516634A (en) Heteroaryl compounds for the treatment of pain
EA200500985A1 (ru) Твердая лекарственная форма для перорального применения
EA200400007A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
SE9901573D0 (sv) New compounds
GEAP202516802A (en) Protac chimeric compound, preparation method thereof and use thereof
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
TW200603816A (en) Risedronate compositions and their methods of use
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2025005154A (es) Formulaciones orales compactables de ibutamoren.
TNSN05246A1 (en) Use of 10-hydroxy-10, 11-dihydrocarbamazepine derivatives for the treatment of affective disorders
MX2026000979A (es) Una forma farmaceutica solida de dosificacion bucodispersable de safinamida
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MX2023009620A (es) Metodos terapeuticos.
SE9901572D0 (sv) New compounds
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
JOP20240259A1 (ar) مناهضات at2r واستخدامها
ZA202404160B (en) Oral solution containing lisdexamfetamine and process for the preparation thereof
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat